Literature DB >> 23136

Studies of cardioselectivity and partial agonist activity in beta-adrenoceptor blockade comparing effects on heart rate and peak expiratory flow rate during exercise.

V M Oh, C M Kaye, S J Warrington, E A Taylor, J Wadsworth.   

Abstract

1 The effects of beta-adrenoceptor antagonists given in single doses by oral or intravenous routes were examined in two double-blind controlled studies performed in healthy volunteers. Heart rate and peak expiratory flow rate (PEFR) were measured at rest and during standardized exercise. 2 Propranolol 80 mg and metoprolol 100 mg orally tended to reduce, and propranolol and metoprolol 0.2 mg/kg intravenously did reduce the physiological increase in PEFR during exercise; oxprenolol 80 mg orally and 0.2 mg/kg intravenously did not. Practolol 200 mg orally reduced this increase, but practolol 1 mg/kg intravenously did not. 3 In a third study of similar design, pindolol 0.05 mg/kg intravenously did not affect exercise-induced increase in PEFR. 4 Heart rate during exercise was reduced to a comparable extent at different times by all the active treatments. 5 Oxprenolol and pindolol share with practolol the property of partial agonist activity, which might contribute to their apparent lack of effect on airways resistance. A further possibility is that alpha-adrenoceptor blockade helps to maintain exercise-induced increase in PEFR.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 23136      PMCID: PMC1429244          DOI: 10.1111/j.1365-2125.1978.tb01609.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Combined pharmacokinetic and pharmacodynammc studies in man of the adrenergic beta1-receptor antagonist metoprolol.

Authors:  G Johnsson; C G Regårdh; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

Review 2.  The assessment of beta-adrenoceptor blocking drugs in man.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

3.  The metabolism and distribution of the selective adrenergic beta blocking agent, practolol.

Authors:  B Scales; M B Cosgrove
Journal:  J Pharmacol Exp Ther       Date:  1970-11       Impact factor: 4.030

4.  Beta-adrenergic blocking drugs.

Authors:  J W Paterson
Journal:  Br Med J       Date:  1971-06-12

5.  Practolol treatment in asthmatics.

Authors:  H J Waal-Manning; F O Simpson
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

6.  Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.

Authors:  G Johnsson; N Svedmyr; G Thiringer
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

7.  Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon.

Authors:  J J Lertora; A L Mark; J Johannsen; W R Wilson; F M Abboud
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

8.  Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors.

Authors:  H H Harms
Journal:  J Pharmacol Exp Ther       Date:  1976-11       Impact factor: 4.030

9.  A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine.

Authors:  W L Pacha
Journal:  Experientia       Date:  1969-08-15

10.  Prevention of exercise-induced asthma by indoramin.

Authors:  S Bianco; J P Griffin; P L Kamburoff; F J Prime
Journal:  Br Med J       Date:  1974-10-05
View more
  30 in total

1.  Current status of Beta blocker therapy.

Authors:  J D Gray
Journal:  Can Fam Physician       Date:  1980-05       Impact factor: 3.275

2.  Beta-adrenoceptor antagonists and respiratory function.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

3.  Beta-adrenoceptor antagonists and respiratory function.

Authors:  W H Perks; S S Chatterjee; R S Croxson; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

4.  Beta-adrenoceptor antagonists and respiratory function.

Authors:  V M Oh; C M Kaye; S J Warrington; E A Taylor; J Wadsworth
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

5.  beta-Adrenoceptor antagonists and respiratory function.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

6.  Beta-adrenoceptor antagonists and respiratory function.

Authors:  C R Kumana
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

7.  Exercise responses of healthy subjects in the evaluation of cardioselectivity of beta-blockers.

Authors:  K L Woods; S P Linton; M J Kendall; E B Faragher; R J Grieve
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

8.  The effect of intrinsic sympathomimetic activity of beta-adrenoceptor blockers on circadian heart rate.

Authors:  P Fitscha; B Tiso; W Meisner; D Spitzer
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

9.  A comparison between propranolol, practolol and betaxolol (SL75212) on the circulatory and metabolic responses to insulin-induced hypoglycaemia.

Authors:  J Saunders; R Gomeni; J R Kilborn; P L Morselli; P H Sönksen
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Influence of environmental temperature and humidity on bronchial responses during assessment of selectivity of beta-adrenoceptor antagonists in man.

Authors:  E A Taylor; P W Trembath; S J Warrington
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.